Circulating IGF-1 levels are consistently reported as lower in individuals with NAFLD compared to matched controls [75–79], and IGF-1 levels are further reduced at advanced stages of steatohepatitis and fibrosis compared with levels in those with simple steatosis [45,78,80–82]. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.